Clinical trials: Kidney (Renal Cell) Cancer
Cancer, Immunotherapy
Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.
This clinical trial aims to evaluate whether a ketogenic diet (KD), when combined with immunotherapy, can improve immune function and treatment outcomes in patients with advanced melanoma, cutaneous squamous cell carcinoma…
- Conditions
- Cancer, Immunotherapy, Ketogenic Diet
- Trial name
- NCT06896552
- Testing
- Ketogenic diet
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Solid Tumor, Adult
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
The main purpose of this study is to evaluate the safety and tolerability of EVT801 in subjects with advanced or metastatic solid tumours.
- Trial name
- NCT05114668
- Testing
- EVT801
- Where
- 2 sites in France
- Volunteers
- 32 people
- Sponsor
- Kazia Therapeutics Limited
Kidney Cancer
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003585
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of New Mexico
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
VEG111485: A QTc Study of Pazopanib
This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in…
- Trial name
- NCT00861029
- Testing
- Pazopanib, Moxifloxacin
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068…
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT06147037
- Testing
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Where
- 8 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated…
- Trial name
- NCT06083922
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where…
- Trial name
- NCT05863351
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- 108 sites in United States
- Volunteers
- 472 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Phase I trial to study the effectiveness of bortezomib in treating patients who have advanced cancer and kidney dysfunction. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00054483
- Testing
- bortezomib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Clear Cell Renal Cell Carcinoma, Neoplasms
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
"This study is a phase 2, randomized study to evaluate the efficacy and safety of SLC-3010 in combination with axitinib versus axitinib monotherapy as second-line treatment in patients with locally advanced or metastatic clear…
- Conditions
- Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms, Malignant Neoplasm of Kidney, Except Renal Pelvis
- Trial name
- NCT07469683
- Testing
- SLC-3010 + Axitinib, Axitinib
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Yonsei University
Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion in treating patients with…
- Conditions
- Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00006251
- Testing
- total-body irradiation, fludarabine phosphate, cyclosporine
- Where
- 2 sites in United States, Italy
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Cell Carcinoma
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial).
- Trial name
- NCT01224288
- Testing
- Perfusion CT scan
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma (RCC), Cancer
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing…
- Trial name
- PROTECT (NCT01235962)
- Testing
- pazopanib
- Where
- 312 sites in United States, Argentina and 24 more
- Volunteers
- 1,538 people
- Sponsor
- Novartis Pharmaceuticals
Radiation Therapy, Metastatic Renal Cancer
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area, with Peking University First Hospital treating over 1,000 kidney cancer patients annually.
- Conditions
- Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
- Trial name
- COSTAR (NCT06583070)
- Testing
- Radiation therapy, Targeted and immunotherapy
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Kidney Cancer, Melanoma (Skin)
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer or melanoma cells.
- Trial name
- NCT00003091
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Renal Cell Carcinoma
Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer
This pilot research trial studies quantitative imaging metrics derived from contrast enhanced computed tomography (CECT) in enhancing assessment of disease status in patients with kidney cancer.
- Trial name
- NCT02370290
- Testing
- Medical Chart Review, Informational Intervention
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Southern California
Renal Cell Carcinoma, Ovarian Carcinoma
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same.
- Conditions
- Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma
- Trial name
- OPTI-DOSE (NCT05949424)
- Testing
- Olaparib, Lenvatinib, Sunitinib
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Clear Cell Renal Cell Carcinoma
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Cadonilimab and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for…
- Trial name
- NCT06138496
- Testing
- Cadonilimab Combined With Lenvatinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University